S3 E3: Brad Loncar on Whether Pricing Pressure is Coming in Oncology

Redeeming Value

Content provided by W2O Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by W2O Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

3y ago 24:33

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on May 30, 2023 00:27 (1+ y ago). Last successful fetch was on April 25, 2023 10:11 (1+ y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Launch prices in oncology have been rising -- a reflection, in part, of the growing clinical power of the medicines -- raising the question whether doctors, payers and others might try to push down prices of cancer medicines. Loncar Investment's Brad Loncar joins us to lend his perspective on the issue in a conversation that touches on the rise of Chinese biotech and the question of whether insurance companies are willing or able to intervene in the oncology market.

16 episodes

#Business News #Medicine #Access #Biotechnology #Drugpricing #Healthcare #Healtheconomics #Healthinsurance #Healthpolicy #Medical #Pbms #Pharmaceutical #Reimbursement #Value #Fitness #News #W2O Groups #Health and Well-Being